P2RY12 and Patent foramen ovale: In this systematic review and meta-analysis, we enrolled four studies for a total of 262 migraine patients with or without PFO, and three studies involved 539 patients for the prevention of new-onset migraine attacks following ASDC with the antiplatelet treatment of the platelet P2Y12 inhibitor.